COPD

News

AZ pays $200m upfront for Sino Bio COPD drug

AstraZeneca has licensed a drug candidate for COPD from China's Sino Bio, which could compete with MSD's Ohtuvayre, in a deal valued at up to $2.1bn.

News

Zymeworks cuts deal to buy Theravance for $929m in cash

Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.

News

AZ is three for three with COPD hope tozorakimab

AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.

News

Where others missed, AZ's IL-33 drug hits the mark in COPD

AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.

News

Generate's IPO gets over the line, raising $400m

AI-powered drug developer Generate Biomedicine completes a $400m IPO, the largest for biotech on the Nasdaq so far this year.

News

COPD patients will get access to Dupixent via NHS

Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.

AZ pays $200m upfront for Sino Bio COPD drug

Zymeworks cuts deal to buy Theravance for $929m in cash

AZ is three for three with COPD hope tozorakimab

Where others missed, AZ's IL-33 drug hits the mark in COPD

Generate's IPO gets over the line, raising $400m

COPD patients will get access to Dupixent via NHS

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

COPD

Editor's Picks